Equities

Charles River Laboratories International Inc

Charles River Laboratories International Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)209.62
  • Today's Change3.52 / 1.71%
  • Shares traded707.87k
  • 1 Year change+0.52%
  • Beta1.3590
Data delayed at least 15 minutes, as of Sep 20 2024 00:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy3
Outperform4
Hold13
Sell0
Strong Sell0

Share price forecast in USD

The 14 analysts offering 12 month price targets for Charles River Lbrtrs ntrntl Inc have a median target of 220.00, with a high estimate of 259.21 and a low estimate of 191.00. The median estimate represents a 4.95% increase from the last price of 209.62.
High23.7%259.21
Med5.0%220.00
Low-8.9%191.00

Earnings history & estimates in USD

On Aug 07, 2024, Charles River Lbrtrs ntrntl Inc reported 2nd quarter 2024 earnings of 2.80 per share. This result exceeded the 2.39 consensus of the 16 analysts covering the company and exceeded last year's 2nd quarter results by 4.09%.
The next earnings announcement is expected on Nov 06, 2024.
Average growth rate+1.80%
Charles River Lbrtrs ntrntl Inc reported annual 2023 earnings of 10.67 per share on Feb 14, 2024.
Average growth rate+12.86%
More ▼

Revenue history & estimates in USD

Charles River Laboratories International, Inc. had 2nd quarter 2024 revenues of 1.03bn. This bettered the 1.02bn consensus of the 14 analysts covering the company. This was 0.32% below the prior year's 2nd quarter results.
Average growth rate-0.79%
Charles River Laboratories International, Inc. had revenues for the full year 2023 of 4.13bn. This was 3.86% above the prior year's results.
Average growth rate+12.20%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.